22 results on '"Brulle-Wohlhueter C"'
Search Results
2. Visceral, subcutaneous abdominal adiposity and liver fat content distribution in normal glucose tolerance, impaired fasting glucose and/or impaired glucose tolerance
3. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes
4. Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: results from INSPIRE ME IAA
5. Hypoglykämie als Funktion des HbA1c bei Typ-2-Diabetes mellitus (T2DM): Insulin glargin 300 E/ml in einer Metaanalyse auf Patientenebene der Studien EDITION 1, 2 und 3
6. Glykämische Kontrolle und Hypoglykämierisiko unter Insulin Glargin 300 E/ml (Gla-300) vs. Glargin 100 E/ml (Gla-100) bei Typ-2-Diabetes (T2DM) in einer Patient-Level Metaanalyse der 1-Jahres-Daten aus den EDITION Phase-IIIa-Studien
7. CA-180: La quantité et la densité du tissu adipeux viscéral, mesurés par tomodensitométrie, sont indépendamment associées au profil de risque cardiométabolique : résultats de l'étude internationale INSPIRE ME IAA
8. Patient‐level meta‐analysis of theEDITION1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes
9. P288 Résultats d’une enquête destinée à évaluer la fonctionnalité et la facilité d’utilisation du stylo Gla-300 SoloSTAR par rapport à trois autres stylos préremplis commercialisés
10. Visceral, subcutaneous abdominal adiposity and liver fat content distribution in normal glucose tolerance, impaired fasting glucose and/or impaired glucose tolerance
11. eTRANSAFE: data science to empower translational safety assessment.
12. Brief Digital Solutions in Behavior Change Interventions for Type 2 Diabetes Mellitus: A Literature Review.
13. Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis.
14. Erratum. A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care 2018;41:1672-1680.
15. Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3.
16. A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study.
17. Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA.
18. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes.
19. Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes.
20. Reply: To PMID 25499404.
21. Usability of the Gla-300 Injection Device Compared With Three Other Commercialized Disposable Insulin Pens: Results of an Interview-Based Survey.
22. Usefulness of measuring both body mass index and waist circumference for the estimation of visceral adiposity and related cardiometabolic risk profile (from the INSPIRE ME IAA study).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.